Jump to content
World's Largest Herpes Support Group
Sign in to follow this  
Margaux

suppressive therapy question~

Recommended Posts

Margaux

I was just diagnosed with herpes in the beginning of November. My body is still not making antibodies as I tested negative by blood test today. This was my second test. I know some people don't show antibodies until three or more months after exposure, so it is normal to still show a negative reading. I have been on Valtrex since the day I was diagnosed and had planned to continue taking it continuously to avoid outbreaks.My question is this: Is my taking of antivirals on a daily basis a bad thing ? Should I allow my body to make the antibodies and then consider going back on the meds?

Share this post


Link to post
Share on other sites
JBnATL

Are you in a relationship with a person who does not have this? If so, taking daily meds can reduce the risk of transmission by 50%.

However, if you are not seeing someone, and your outbreaks are not that severe then you might want to stop taking them and let your body get used to dealing with the virus with out the crutch of taking meds.

Good luck!

JB

Share this post


Link to post
Share on other sites
Margaux

Hi JB, I am married. My husband has HSV genitally and orally. He was diagnosed 25 years ago and does not know if he has type I, II or both. I have managed to escape it for 14 years. Me getting this virus was an eventuality. I still do not know if I have type I or II. In a way, it does not matter as we will not change our sex life because of this. I would like to know the type I have and need to see this diagnosis in writing even though it is quite clear what I have. I didn't know if going off the meds would make things very bad for me as I have been on them for 6 or 7 weeks and have felt soooo sick (flu-ish) the whole time with the exception of about three days. I also didn't know if the meds were impeding my body from making the antibodies. Thanks for your response.

Share this post


Link to post
Share on other sites
death2herpes

it is possible for suppressive therapy started immediately to delay IGG test seroconversion (not sure how much they can significantly affect the entire immune response though, which is more complex than just the IGG titres). but that may well be a contributing factor to your still negative test results. or if it's HSV1, it may not be showing up, or ever show up, bc the test is not as sensitive to some HSV1 strains as to HSV2.

but i don't see a downside to trying a break from the antivirals -- you may end up having mild, infrequent or no recurrences so you may not even require them and are just taking them needlessly at this point since there is noone for you to protect from transmission. especially since the symptoms you describe may be side effects of the medication.

Share this post


Link to post
Share on other sites
Margaux

Thanks very much, death2h. I finished the RX I had and am gonna try having my immune system flying solo and see what happens. I have read that the blood test can miss 1/10 cases of hsv1. Thanks again.

Share this post


Link to post
Share on other sites
ktbabii35

i havent been tested for antibodies. i contracted herpes in august... and found out in december. why would i need to be tested for antibodies?

Share this post


Link to post
Share on other sites
death2herpes

well, if you say you found out 4 months later and it was not by AB test then it was culture or PCR. which presumably was typed so you know you have that type. but if you were not tested for ABs then you don't know whether you have the other type too...

Share this post


Link to post
Share on other sites
Lattegirl
i havent been tested for antibodies. i contracted herpes in august... and found out in december. why would i need to be tested for antibodies?

Because you can't diagnose herpes by symptoms alone. You could have HPV, which sets you up for cervical cancer. If you have antibodies, then the virus has been in your body. A PCR or culture will tell you if you have virus in your system, but these are only positive if you are shedding virus or have active virus (not latent). Thus, without a definitive test, everything is just speculation.

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  

  • The Hive is Thriving!

    • Total Topics
      70,110
    • Total Posts
      473,852
  • Posts

    • RNY18
      https://markets.businessinsider.com/news/stocks/x-vax-technology-raises-56-million-in-upsized-series-a-financing-to-advance-lead-herpes-vaccine-program-1028376554 Add ∆gD-2 (delta gD-2) to the list ! "We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity," added William Jacobs, PhD, co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine."...
    • RNY18
      More X-Vax Info : https://markets.businessinsider.com/news/stocks/x-vax-technology-raises-56-million-in-upsized-series-a-financing-to-advance-lead-herpes-vaccine-program-1028376554 "We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity," added William Jacobs, PhD, co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine..."
    • RNY18
      They may not cure HSV but it looks like they are taking positive steps against HIV : https://timesofindia.indiatimes.com/life-style/health-fitness/he alth-news/hiv-cure-soon-human-trials-underway-in-china/articleshow/70316379.cms   "Hopefully, the second-phase trial will be completed in the latter half of 2021, and the third-phase clinical trial may start at the end of that year, which will involve thousands of volunteers in a trial to test the effectiveness of the vaccine to protect people against HIV," the researcher added."...  
    • RNY18
      Got this this morning, definitely positive news. Still seems so far off....
    • RNY18
      X-Vax Technology Raises $56 Million in Upsized Series A Financing to Advance Lead Herpes Vaccine Program A new approach to beating herpes by inducing antibodies that mediate the killing of infected cells Participants include Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; Founders Fund.  JUPITER, FL, July 23, 2019. X-Vax Technology, Inc. (X-VAX), a biotechnology company developing vaccines based on a new approach that mediates the killing of infected cells, today announced that it has raised $56 million in an upsized Series A financing with participation from strategic and institutional investors, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; and FF DSF VI, a scout investment vehicle out of Founders Fund. Proceeds from the financing will be used to advance X-VAX’s lead program, a vaccine candidate against herpes, called ∆gD-2 (delta gD-2) for further development and production, including a Phase 1 clinical study.   “We are pleased to have the support of our new and existing investors as we continue to build our leadership position in the development of a herpes vaccine,” said Ulf Wiinberg, President and Chief Executive Officer of X-VAX. “We are encouraged by the preclinical data for our new approach to beating herpes and creating a potentially world-changing vaccine.”    “Herpes infections are a significant global health problem that affect all age groups from infants to the elderly. Infection is associated with a wide range of disease,” said Betsy Herold, MD, co-Inventor and Professor of Pediatrics, Microbiology & Immunology at Albert Einstein College of Medicine in New York. “The ability of the virus to successfully escape clearance by the immune system and to establish a non-replicating state known as latency with periodic reactivation results in lifelong infection and ongoing risk of transmission.”    “We believe that ∆gD-2 may be more promising than other previous vaccine candidates because it elicits a different type of immune response against HSV-1 and HSV-2 that is more effective in preclinical models at clearing virus and preventing the establishment of latency. In nonclinical models, immunization with ∆gD-2 elicits antibodies that facilitate the killing of infected cells, rapidly clearing the virus and thereby inducing sterilizing immunity,” added William Jacobs, PhD, co-Inventor and Professor of Microbiology & Immunology at Albert Einstein College of Medicine.   Maxim Merchant Capital, a division of Maxim Group LLC, acted as sole placement agent for the financing.   About herpes, a global epidemic There is no approved vaccine for herpes simplex. Herpes simplex virus is categorized into 2 types: herpes simplex virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2). More than 3.7 billion people under the age of 50 around the world are infected with HSV-1, while over 400 million have HSV-2. Neonatal infection can be devastating, at 60% fatality without treatment. Other complications include encephalitis or meningitis (inflammation of the brain or the tissue that covers the brain and spinal cord), and infectious blindness. HSV-2 is also known to contribute significantly to the spread of HIV. Antiviral drug therapy shows only moderate efficacy and comes with significant side effects. Attempts to develop an effective vaccine have repeatedly failed.   About X-Vax Technology, Inc. We are a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we are taking could succeed in defeating herpes. We have created a herpes vaccine candidate that we call ∆gD-2 (delta gD-2) because it is based on an HSV-2 virus genetically deleted for glycoprotein D (gD-2). With it, we have been able to prevent infections caused by herpes type 1 (HSV-1) and type 2 (HSV-2) in multiple preclinical models—with encouraging results. The vaccine induces Fc receptor activating antibodies that mediate antibody-dependent cell-mediated killing (ADCK) as the primary mechanism of protection. ADCK is induced to flag infected cells for destruction by natural immune cells.   Forward-looking statements This news release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, we are using forward-looking statements when we discuss the proposed use of proceeds from the Series A financing, when we describe our belief that our new approach to beating herpes could succeed in potentially creating a world-changing vaccine, when we discuss the belief that our vaccine candidate is more promising than other previous vaccine candidates and when we state our belief that our new approach could succeed in defeating herpes. These forward-looking statements and their implications are based on the current expectations of the management of X-VAX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation may adversely impact us inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of X-VAX to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.    Contact Andreas Eggert aeggert@x-vax.com +1-561-517-XVAX (+1-561-517-9829)   x-vax.com  
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.